Ventyx Biosciences, Inc.

NasdaqGS:VTYX Stock Report

Market Cap: US$168.9m

Ventyx Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

Ventyx Biosciences has a total shareholder equity of $280.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $309.2M and $28.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$239.44m
EquityUS$280.80m
Total liabilitiesUS$28.40m
Total assetsUS$309.19m

Recent financial health updates

Recent updates

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Jul 12
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)

Jul 01

Ventyx Pivots To Obesity Amid Transformation

Mar 12

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Feb 15
Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Ventyx: Too Risky Right Now After Some Poor Data

Jan 18

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

Sep 21
Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Feb 20
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Ventyx Biosciences: Not Chasing This Rally

Sep 18

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Aug 19
We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06

Aug 15

Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals

Jun 29

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

May 06
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Jan 21
We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Financial Position Analysis

Short Term Liabilities: VTYX's short term assets ($256.9M) exceed its short term liabilities ($18.1M).

Long Term Liabilities: VTYX's short term assets ($256.9M) exceed its long term liabilities ($10.3M).


Debt to Equity History and Analysis

Debt Level: VTYX is debt free.

Reducing Debt: VTYX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VTYX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VTYX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 59.9% each year.


Discover healthy companies